Scarica l'app Stockscreener
8.74
1.47%
-0.13
Dopo l'orario di chiusura:
8.61
-0.13
-1.49%
Precedente Chiudi:
$8.87
Aprire:
$9
Volume 24 ore:
128.69K
Relative Volume:
1.39
Capitalizzazione di mercato:
$841.78M
Reddito:
$106.66M
Utile/perdita netta:
$15.16M
Rapporto P/E:
93.48
EPS:
0.0935
Flusso di cassa netto:
$6.37M
1 W Prestazione:
+22.24%
1M Prestazione:
+15.15%
6M Prestazione:
+10.08%
1 anno Prestazione:
-37.53%
Intervallo 1D:
$8.70
$9.42
Intervallo di 1 settimana:
$7.75
$9.42
Portata 52W:
$6.11
$19.00
Gyre Therapeutics Inc Stock (GYRE) Company Profile
Nome
Gyre Therapeutics Inc
Settore
Industria
Telefono
(619) 949-3681
Indirizzo
12770 HIGH BLUFF DRIVE, SUITE 150, SAN DIEGO
Confronta GYRE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GYRE
Gyre Therapeutics Inc
|
8.74 | 727.52M | 106.66M | 15.16M | 6.37M | 0.0935 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Gyre Therapeutics Inc Stock (GYRE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-10 | Iniziato | Jefferies | Buy |
| 2025-08-26 | Iniziato | H.C. Wainwright | Buy |
| 2025-03-11 | Iniziato | Noble Capital Markets | Outperform |
| 2021-04-29 | Ripresa | Stephens | Overweight |
| 2021-02-10 | Iniziato | Piper Sandler | Overweight |
| 2020-05-21 | Iniziato | Raymond James | Outperform |
| 2019-01-04 | Iniziato | Oppenheimer | Outperform |
| 2018-02-12 | Reiterato | B. Riley FBR, Inc. | Buy |
| 2018-02-09 | Reiterato | Chardan Capital Markets | Buy |
| 2017-12-08 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2017-06-12 | Iniziato | Chardan Capital Markets | Buy |
| 2017-06-06 | Iniziato | Ladenburg Thalmann | Buy |
| 2016-06-30 | Iniziato | Rodman & Renshaw | Buy |
Mostra tutto
Gyre Therapeutics Inc Borsa (GYRE) Ultime notizie
H.C. Wainwright reiterates Buy rating on Gyre Therapeutics stock at $18 - Investing.com
GNI's Gyre Therapeutics Completes Enrollment for Phase 3 Pneumoconiosis Drug Trial - MarketScreener
What dividend safety score for Gyre Therapeutics Inc. stock2025 Buyback Activity & Expert Verified Stock Movement Alerts - newser.com
Will breakout in Gyre Therapeutics Inc. lead to full recoveryJuly 2025 Retail & Weekly Momentum Picks - newser.com
What momentum shifts mean for Gyre Therapeutics Inc.Quarterly Market Review & Momentum Based Trading Signals - newser.com
Gyre Therapeutics Announces Completion of Patient - GlobeNewswire
272 Patients Enrolled — Gyre Therapeutics' Phase 3 Pirfenidone Trial Completes at 18 China Sites - Stock Titan
Using Ichimoku Cloud for Gyre Therapeutics Inc. technicalsWeekly Stock Summary & Verified Momentum Stock Alerts - newser.com
MarketsMedicine Hat News - FinancialContent
High Growth US Tech Stocks To Watch In October 2025 - Yahoo Finance
Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD-The Liver Meeting® 2025 - The Manila Times
Gyre Therapeutics to Present Positive Phase 3 Trial Results of Hydronidone for Liver Fibrosis at The Liver Meeting® 2025 - Quiver Quantitative
Gyre Therapeutics to Present Results from Positive Phase 3 - GlobeNewswire
Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025 - Stock Titan
How to integrate Gyre Therapeutics Inc. into portfolio analysis toolsJuly 2025 Selloffs & Accurate Technical Buy Alerts - newser.com
Using fundamentals and technicals on Gyre Therapeutics Inc.Stop Loss & Fast Gain Stock Trading Tips - newser.com
Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Up – Should You Buy? - Defense World
Gyre Therapeutics (NASDAQ:GYRE) Shares Gap UpHere's Why - MarketBeat
Gyre Therapeutics Stock Price, Quotes and Forecasts - Benzinga
Jefferies initiates Gyre Therapeutics stock with Buy rating, $16 target By Investing.com - Investing.com Nigeria
Visual trend scoring systems applied to Gyre Therapeutics Inc.2025 Valuation Update & Risk Controlled Stock Pick Alerts - newser.com
This Aptiv Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Jefferies Initiates Coverage on Gyre Therapeutics (GYRE) with a "Buy" Rating | GYRE Stock News - GuruFocus
Jefferies Initiates Coverage of Gyre Therapeutics (GYRE) with Buy Recommendation - Nasdaq
Jefferies Initiates Coverage on Gyre Therapeutics With Buy Rating, $16 Price Target - MarketScreener
Jefferies initiates Gyre Therapeutics stock with Buy rating, $16 target - Investing.com
Gyre Therapeutics (NASDAQ:GYRE) Earns Sell (D) Rating from Weiss Ratings - MarketBeat
Gyre Therapeutics Inc Stock Analysis and ForecastCandlestick Pattern Analysis & Small Investment Portfolio - earlytimes.in
Can momentum traders help lift Gyre Therapeutics Inc.Weekly Trend Report & Safe Entry Point Identification - newser.com
Gyre Therapeutics Inc. stock outlook for YEARJuly 2025 Big Picture & Low Drawdown Investment Ideas - newser.com
Volatility clustering patterns for Gyre Therapeutics Inc.Portfolio Value Summary & Short-Term Swing Trade Alerts - newser.com
Real time alert setup for Gyre Therapeutics Inc. performanceTrade Risk Report & Free Expert Approved Momentum Trade Ideas - newser.com
Gyre Therapeutics president Ma Songjiang sells $42,760 in stock - MSN
Discovering 3 Undiscovered Gems In The US Market - simplywall.st
Goldman Sachs Group Inc. Cuts Stock Position in Gyre Therapeutics, Inc. $GYRE - Defense World
Developing predictive dashboards with Gyre Therapeutics Inc. dataPortfolio Performance Report & AI Forecast Swing Trade Picks - newser.com
Gyre Therapeutics Inc Azioni (GYRE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Gyre Therapeutics Inc Azioni (GYRE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Ma Songjiang | President |
May 28 '25 |
Sale |
10.07 |
558 |
5,619 |
2,806,084 |
| Ma Songjiang | President |
May 22 '25 |
Sale |
10.97 |
2,000 |
21,940 |
2,808,824 |
| Ma Songjiang | President |
May 23 '25 |
Sale |
10.24 |
182 |
1,864 |
2,808,642 |
| Ma Songjiang | President |
May 20 '25 |
Sale |
11.25 |
2,000 |
22,500 |
2,812,824 |
| Ma Songjiang | President |
May 21 '25 |
Sale |
10.83 |
2,000 |
21,660 |
2,810,824 |
| Ma Songjiang | President |
May 16 '25 |
Sale |
11.31 |
2,000 |
22,620 |
2,816,824 |
| Ma Songjiang | President |
May 19 '25 |
Sale |
11.11 |
2,000 |
22,220 |
2,814,824 |
| Ma Songjiang | President |
May 15 '25 |
Sale |
10.68 |
2,000 |
21,360 |
2,818,824 |
| Ma Songjiang | President |
May 14 '25 |
Sale |
11.30 |
20 |
226 |
2,820,824 |
| Ye Weiguo | Chief Operating Officer |
Apr 01 '25 |
Option Exercise |
0.75 |
50,000 |
37,500 |
700,000 |
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):